Supriya Lifescience Ltd
Supriya Lifescience is engaged in the manufacturing of Active pharmaceutical ingredients (APIs). As of March 31, 2021, the company produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic.[1]
- Market Cap ₹ 5,309 Cr.
- Current Price ₹ 662
- High / Low ₹ 842 / 511
- Stock P/E 29.8
- Book Value ₹ 124
- Dividend Yield 0.15 %
- ROCE 27.4 %
- ROE 20.7 %
- Face Value ₹ 2.00
Pros
- Company is almost debt free.
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|
184 | 213 | 278 | 312 | 391 | 530 | 461 | 570 | 696 | 681 | |
166 | 191 | 213 | 213 | 218 | 316 | 332 | 394 | 436 | 431 | |
Operating Profit | 17 | 22 | 65 | 98 | 173 | 214 | 129 | 176 | 261 | 250 |
OPM % | 9% | 10% | 23% | 32% | 44% | 40% | 28% | 31% | 37% | 37% |
7 | 9 | 8 | 11 | 5 | 8 | 9 | 11 | 10 | 10 | |
Interest | 12 | 11 | 10 | 7 | 4 | 4 | 3 | 5 | 2 | 2 |
Depreciation | 5 | 5 | 5 | 6 | 7 | 10 | 12 | 16 | 20 | 22 |
Profit before tax | 8 | 14 | 57 | 96 | 167 | 207 | 123 | 166 | 248 | 236 |
Tax % | 30% | 40% | 31% | 24% | 26% | 27% | 27% | 28% | 24% | |
6 | 9 | 39 | 73 | 124 | 152 | 90 | 119 | 188 | 178 | |
EPS in Rs | 3.87 | 5.96 | 26.93 | 50.11 | 16.89 | 18.86 | 11.17 | 14.80 | 23.35 | 22.12 |
Dividend Payout % | 0% | 0% | 0% | 20% | 3% | 3% | 5% | 5% | 4% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 17% |
3 Years: | 10% |
TTM: | 14% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 21% |
3 Years: | 7% |
TTM: | 32% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 23% |
1 Year: | 23% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 23% |
3 Years: | 17% |
Last Year: | 21% |
Balance Sheet
Figures in Rs. Crores
Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|
Equity Capital | 15 | 15 | 15 | 15 | 15 | 16 | 16 | 16 | 16 |
Reserves | 31 | 40 | 79 | 134 | 254 | 600 | 683 | 799 | 981 |
140 | 130 | 90 | 82 | 72 | 27 | 22 | 5 | 5 | |
55 | 60 | 69 | 105 | 105 | 92 | 98 | 100 | 110 | |
Total Liabilities | 241 | 245 | 253 | 336 | 445 | 735 | 820 | 921 | 1,112 |
89 | 91 | 85 | 99 | 100 | 190 | 262 | 310 | 453 | |
CWIP | 36 | 34 | 35 | 40 | 79 | 43 | 68 | 149 | 148 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 25 | 64 | 63 |
117 | 120 | 133 | 197 | 267 | 502 | 466 | 398 | 448 | |
Total Assets | 241 | 245 | 253 | 336 | 445 | 735 | 820 | 921 | 1,112 |
Cash Flows
Figures in Rs. Crores
Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|
27 | 28 | 49 | 117 | 76 | 49 | 64 | 113 | 165 | |
-27 | -5 | 5 | -25 | -47 | -60 | -124 | -174 | -152 | |
-2 | -20 | -50 | -29 | -15 | 150 | -10 | -22 | -8 | |
Net Cash Flow | -2 | 3 | 4 | 62 | 15 | 139 | -70 | -83 | 4 |
Ratios
Figures in Rs. Crores
Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|
Debtor Days | 99 | 92 | 79 | 60 | 69 | 79 | 67 | 71 | 70 |
Inventory Days | 113 | 85 | 77 | 130 | 206 | 172 | 234 | 140 | 205 |
Days Payable | 121 | 112 | 110 | 130 | 145 | 91 | 130 | 98 | 129 |
Cash Conversion Cycle | 91 | 64 | 45 | 61 | 130 | 160 | 171 | 114 | 146 |
Working Capital Days | -69 | -50 | -5 | -40 | 28 | 117 | 168 | 157 | 144 |
ROCE % | 14% | 37% | 50% | 60% | 43% | 19% | 22% | 27% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
1d - Copy of Newspaper Publication regarding intimation of dispatch of Annual Report, AGM Notice and E-voting Instructions.
-
Intimation Under Regulation 30 Regarding Letter Dispatched To The Shareholders Of The Company Providing Weblink
1d - Annual Report FY2024-25 and 17th AGM notice uploaded; web-link provided (Sept 1, 2025).
-
Business Responsibility and Sustainability Reporting (BRSR)
1d - AGM on September 24, 2025; Annual Report FY2024-25 and BRSR filed and circulated.
-
Reg. 34 (1) Annual Report.
1d - AGM on September 24, 2025; Annual Report FY2024-25 and BRSR published, available on company website.
-
Notice Of 17Th Annual General Meeting Of Members Of The Company Scheduled To Be Held On Wednesday, September 24, 2025.
1d - AGM on Sep 24, 2025; FY2024-25 annual report filed; final dividend Re.1; auditors appointed; record date Sep 5.
Annual reports
Concalls
-
Aug 2025Transcript PPT REC
-
May 2025Transcript PPT REC
-
Jan 2025Transcript PPT REC
-
Nov 2024Transcript PPT REC
-
Aug 2024Transcript PPT REC
-
Jun 2024Transcript PPT REC
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT REC
-
Aug 2023Transcript PPT REC
-
Jun 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
May 2022TranscriptNotesPPT
-
Feb 2022TranscriptPPT
-
Jan 2022Transcript PPT
Niche Products Offerings[1]
Supriya Lifescience Ltd. has a niche product basket of 40+ APIs and is a global leader in Anti-histamines, anti-allergy, Vitamins, Anti-Asthmatics, & Anesthetics. They utilize a backward-integrated model for 15 products and possess the ability to handle complex chemistries and controlled substances.